{"entity":{"id":"nct05965856","kind":"trial","name":"A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid Tumors","aka":[],"tldr":"A phase 2 trial of BL-B01D1 in bladder & urothelial cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.","summary":"A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid Tumors is a phase 2 interventional study registered as NCT05965856 by Sichuan Baili Pharmaceutical Co., Ltd., with 52 participants planned, started 2023-12-11 and due to reach its primary completion in 2026-12. Interventions recorded: BL-B01D1 and SI-B003.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05965856","url":"https://clinicaltrials.gov/study/NCT05965856"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["urothelial","muscle-invasive-bladder-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["systimmune"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05965856","phase":"2","setting":"A Phase II Clinical Study to Evaluate the Efficacy and Safety of SI-B003 Monotherapy and BL-B01D1+SI-B003 Combination Therapy (BL-B01D1+SI-B003) in Patients With Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid Tumors","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","participation":[{"nct":"NCT05965856","source":"https://clinicaltrials.gov/study/NCT05965856","fetchedAt":"2026-10-07T16:54:03.729Z","studySha256":"104e9803d723fdd6a4e162e68efb0dbd3f84657663bcdcc2da8fdbebd90c4b35","overallStatus":"RECRUITING","lastUpdatePosted":"2025-09-26","leadSponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"75 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":52,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":1,"countries":["China"]}],"started":"2023-12-11","startedType":"actual","enrolled":52,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05965856/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"},{"id":"muscle-invasive-bladder-cancer","kind":"cancer","name":"Muscle-invasive and advanced bladder cancer","route":"/cancers/muscle-invasive-bladder-cancer/"}],"company":[{"id":"systimmune","kind":"company","name":"SystImmune / Sichuan Biokin","route":"/companies/systimmune/"}]}}